A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
This study is testing a new medication called VERT-002 to see how safe it is and how well it works for people with advanced solid tumors or non-small cell lung cancer. Researchers want to find the best and safest dose of this investigational medicine to help patients with specific genetic changes.
You may be able to join if you have advanced cancer with specific changes in your MET gene, such as exon 14 skipping or kinase domain mutations. Participants must also meet general health guidelines and have well-controlled conditions, especially if cancer has previously spread to the brain or spinal cord.
During the study, you will receive the investigational medication VERT-002 while doctors closely monitor your health, side effects, and how your body responds to the treatment. The team will figure out the optimal dose to use safely through careful check-ups and testing.
This study is currently recruiting participants at multiple medical centers located in Washington D.C., Ohio, and Tennessee. You can talk to your care team to see if one of these locations is convenient for you.
- 1Testing a new medicine named VERT-002 for certain types of advanced cancer.
- 2Specifically looking for patients with MET gene alterations like exon 14 skipping.
- 3Currently recruiting patients at study locations in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.